AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1290609 — intervention group
Group type: COMPARATOR
Intervention: Distilled H2O only (Control)
Number of subjects: 25
Study 1290609 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 ppm F-
Number of subjects: 25
Study 1290609 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 ppm F-
Number of subjects: 25
Study 1290609 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 ppm F-
Number of subjects: 25
Study 1290609 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 ppm F-
Number of subjects: 25
Study 6373331 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.125% clonidine
Number of subjects: 24
Study 6373331 — intervention group
Group type: COMPARATOR
Intervention: Fellow placebo-treated eyes
Number of subjects: 24
Study 31537473 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (30-40 sessions, 100% oxygen, breathed at a pressure of 240-250 kPa, for 80-90 min daily)
Number of subjects: 79
Study 31537473 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 79
Study 30052208 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.8 μg/kg/h)
Number of subjects: 50
Study 30052208 — intervention group
Group type: COMPARATOR
Intervention: Propofol (1.5 mg/kg/h)
Number of subjects: 50
Study 27064889 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback respiratory exercise
Number of subjects: 30
Study 27064889 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragm respiratory exercise
Number of subjects: 30
Study 23672209 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin injection with needle electromyographic guidance (Group A, 15 patients)
Number of subjects: 27
Study 23672209 — intervention group
Group type: COMPARATOR
Intervention: Botulinum toxin injection without electromyographic guidance (Group B, 12 patients)
Number of subjects: 27
Study 23672209 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 27
Study 23135189 — intervention group
Group type: EXPERIMENTAL
Intervention: Flowable resin and self‐etching adhesive (Group A)
Number of subjects: 0
Study 23135189 — intervention group
Group type: COMPARATOR
Intervention: Flowable resin and phosphate acid system (Group B)
Number of subjects: 0
Study 21312293 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine inhalers
Number of subjects: 24
Study 21312293 — intervention group
Group type: COMPARATOR
Intervention: Placebo inhalers
Number of subjects: 24
Study 17666915 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg/day
Number of subjects: 53
Study 17666915 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 80 mg/day
Number of subjects: 53
Study 17666915 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg/day and Valsartan 80 mg/day (combination)
Number of subjects: 53
Study 17666915 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 15020512 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (300 mg/day for three weeks)
Number of subjects: 60
Study 12518121 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 million IU streptokinase (Group A)
Number of subjects: 56
Study 12518121 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg t-PA (Group B)
Number of subjects: 56
Study 12518121 — intervention group
Group type: COMPARATOR
Intervention: No thrombolytic therapy (Group C)
Number of subjects: 56
Study 9690729 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg b.d. + Amoxycillin 500 mg t.d.s. for 2 weeks (Study 1)
Number of subjects: 182
Study 9690729 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg b.d. + Amoxycillin 1 g t.d.s. for 2 weeks (Study 2)
Number of subjects: 182
Study 9690729 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg b.d. + Amoxycillin 1 g t.d.s. for 2 weeks (Study 3)
Number of subjects: 182
Study 9690729 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole monotherapy
Number of subjects: 182
Study 9690729 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin monotherapy
Number of subjects: 182
Study 8089770 — intervention group
Group type: COMPARATOR
Intervention: Water exercise (Veterans group, N = 27, exercising for 35.2 months on average)
Number of subjects: 97
Study 8089770 — intervention group
Group type: COMPARATOR
Intervention: Water exercise (Newcomers group, N = 40, exercising for 3-4 weeks)
Number of subjects: 97
Study 8089770 — intervention group
Group type: COMPARATOR
Intervention: Non-exercisers (N = 30)
Number of subjects: 97
Study 8089770 — intervention group
Group type: COMPARATOR
Intervention: Water exercise (Veterans group, N = 20)
Number of subjects: 97
Study 8089770 — intervention group
Group type: COMPARATOR
Intervention: Water exercise (general awareness of health and fitness)
Number of subjects: 97
Study 2698566 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 90 mg
Number of subjects: 0
Study 2698566 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 120 mg
Number of subjects: 0
Study 2698566 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 180 mg
Number of subjects: 0
Study 2698566 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallopamil 25 mg
Number of subjects: 0
Study 2698566 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallopamil 50 mg
Number of subjects: 0
Study 2698566 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallopamil 100 mg
Number of subjects: 0
Study 2698566 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (Capsule) 5 mg
Number of subjects: 0
Study 2698566 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (Capsule) 10 mg
Number of subjects: 0
Study 2698566 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (Capsule) 20 mg
Number of subjects: 0
Study 2698566 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (Tablet) 20 mg
Number of subjects: 0
Study 2698566 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (Tablet) 40 mg
Number of subjects: 0
Study 2698566 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (Tablet) 60 mg
Number of subjects: 0
Study 2698566 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiapamil 300 mg
Number of subjects: 0
Study 2698566 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiapamil 600 mg
Number of subjects: 0
Study 1093655 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin, 500 mg, 4 times daily for 10 days
Number of subjects: 40
Study 1093655 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole, 4 times daily for 10 days
Number of subjects: 40
Study 31838002 — intervention group
Group type: EXPERIMENTAL
Intervention: Pradefovir 30 mg
Number of subjects: 51
Study 31838002 — intervention group
Group type: EXPERIMENTAL
Intervention: Pradefovir 60 mg
Number of subjects: 51
Study 31838002 — intervention group
Group type: EXPERIMENTAL
Intervention: Pradefovir 75 mg
Number of subjects: 51
Study 31838002 — intervention group
Group type: EXPERIMENTAL
Intervention: Pradefovir 90 mg
Number of subjects: 51
Study 31838002 — intervention group
Group type: EXPERIMENTAL
Intervention: Pradefovir 120 mg
Number of subjects: 51
Study 31838002 — intervention group
Group type: COMPARATOR
Intervention: Adefovir dipivoxil (ADV) 10 mg
Number of subjects: 51
Study 31838002 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate (TDF) 300 mg
Number of subjects: 51
Study 30576013 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin-metformin combination treatment
Number of subjects: 2001
Study 30576013 — intervention group
Group type: COMPARATOR
Intervention: Metformin monotherapy (standard-of-care)
Number of subjects: 2001
Study 28370361 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagenated porcine bone plus cross‐linked collagen membrane
Number of subjects: 30
Study 28370361 — intervention group
Group type: COMPARATOR
Intervention: Collagenated bovine bone plus non‐cross‐linked collagen membrane
Number of subjects: 30
Study 26164709 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIT) group (N = 19)
Number of subjects: 27
Study 26164709 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) (N = 16)
Number of subjects: 27
Study 23438853 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (0.08mg/kg)
Number of subjects: 101
Study 23438853 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine (0.5mg/kg)
Number of subjects: 101
Study 23438853 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 101
Study 21094193 — intervention group
Group type: EXPERIMENTAL
Intervention: Ostracism (induced by a computerized ball-tossing game - Cyberball)
Number of subjects: 0
Study 21094193 — intervention group
Group type: COMPARATOR
Intervention: Inclusion (control condition)
Number of subjects: 0
Study 19877979 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 12
Study 16946209 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic bilateral salpingo-oophorectomy (BSO)
Number of subjects: 106
Study 16946209 — intervention group
Group type: COMPARATOR
Intervention: Surveillance
Number of subjects: 106
Study 14696021 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.25 mg
Number of subjects: 9
Study 14696021 — intervention group
Group type: COMPARATOR
Intervention: Valerian 500 mg
Number of subjects: 9
Study 14696021 — intervention group
Group type: COMPARATOR
Intervention: Valerian 1000 mg
Number of subjects: 9
Study 14696021 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 10933133 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide from metformin/glibenclamide tablets
Number of subjects: 24
Study 8733449 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin eardrops
Number of subjects: 52
Study 8733449 — intervention group
Group type: COMPARATOR
Intervention: Neomycin-polymyxin B-hydrocortisone eardrops
Number of subjects: 52
Study 1415072 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalexin
Number of subjects: 525
Study 1415072 — intervention group
Group type: COMPARATOR
Intervention: Penicillin
Number of subjects: 525
Study 3921585 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (20 cm2 patch)
Number of subjects: 16
Study 3921585 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 30888927 — intervention group
Group type: COMPARATOR
Intervention: Phosphoric acid etching for 15 seconds (G0 - control group)
Number of subjects: 29
Study 30888927 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphoric acid etching for 30 seconds (G1)
Number of subjects: 29
Study 30888927 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound probe applied for 30 seconds (G2)
Number of subjects: 29
Study 29295516 — intervention group
Group type: EXPERIMENTAL
Intervention: MedDiet + EVOO
Number of subjects: 36
Study 29295516 — intervention group
Group type: EXPERIMENTAL
Intervention: MedDiet + nuts
Number of subjects: 36
Study 29295516 — intervention group
Group type: COMPARATOR
Intervention: Low-fat control group
Number of subjects: 36
Study 26025216 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet function testing
Number of subjects: 100
Study 26025216 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100
Study 26025216 — intervention group
Group type: COMPARATOR
Intervention: Untested usual care
Number of subjects: 100
Study 24400838 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-day teacher training
Number of subjects: 193
Study 24400838 — intervention group
Group type: COMPARATOR
Intervention: No teacher training (control)
Number of subjects: 193
Study 22623413 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral alanyl-glutamine (GLN) 25 g twice daily for 3 days preoperatively
Number of subjects: 14
Study 22623413 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin (CONT)
Number of subjects: 14
Study 18829141 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based learning
Number of subjects: 93
Study 18829141 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face learning
Number of subjects: 93
Study 17514499 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59‐adjuvanted subunit vaccine (Sub/MF59)
Number of subjects: 238
Study 17514499 — intervention group
Group type: COMPARATOR
Intervention: Conventional subunit vaccine (Subunit)
Number of subjects: 238
Study 15600247 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV‐AB68 and HCV‐AB65 (HepeX‐C)
Number of subjects: 0
Study 15600247 — intervention group
Group type: COMPARATOR
Intervention: HCV‐AB68 (alone)
Number of subjects: 0
Study 11436117 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF 6 microg/kg/day s.c.
Number of subjects: 156
Study 9807988 — intervention group
Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 1011
Study 9807988 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 1011
Study 7544174 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha 1-blockers
Number of subjects: 0
Study 7544174 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 alpha-reductase inhibitors
Number of subjects: 0
Study 2527819 — intervention group
Group type: EXPERIMENTAL
Intervention: ANF infusion (0.75 pmol/kg/min for 3 hours)
Number of subjects: 6
Study 1067398 — intervention group
Group type: EXPERIMENTAL
Intervention: Free autogenous gingival grafts placed on alveolar bone
Number of subjects: 60
Study 1067398 — intervention group
Group type: COMPARATOR
Intervention: Free autogenous gingival grafts placed on periosteum
Number of subjects: 60
Study 1067398 — intervention group
Group type: EXPERIMENTAL
Intervention: Free autogenous gingival grafts placed on alveolar bone and periosteum
Number of subjects: 60
Study 31060491 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 5
Study 31060491 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin gene‐related peptide
Number of subjects: 5
Study 31060491 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 31060491 — intervention group
Group type: COMPARATOR
Intervention: 3.0 T MR angiography
Number of subjects: 5
Study 31060491 — intervention group
Group type: COMPARATOR
Intervention: 7.0 T MR angiography
Number of subjects: 5
Study 31060491 — intervention group
Group type: COMPARATOR
Intervention: QMra software
Number of subjects: 5
Study 31060491 — intervention group
Group type: EXPERIMENTAL
Intervention: LAVA software
Number of subjects: 5
Study 28287415 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% Ahiflower oil + 70% high oleic sunflower oil
Number of subjects: 88
Study 28287415 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% Ahiflower oil + 40% high oleic sunflower oil
Number of subjects: 88
Study 28287415 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% Ahiflower oil
Number of subjects: 88
Study 28287415 — intervention group
Group type: COMPARATOR
Intervention: 100% high oleic sunflower oil
Number of subjects: 88
Study 25749010 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral wedge insoles
Number of subjects: 70
Study 25749010 — intervention group
Group type: COMPARATOR
Intervention: Control shoe
Number of subjects: 70
Study 23648392 — intervention group
Group type: EXPERIMENTAL
Intervention: Need-based intervention (50g/day soy-protein-based nutritional supplement)
Number of subjects: 92
Study 23648392 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 92
Study 23648392 — intervention group
Group type: EXPERIMENTAL
Intervention: Need-based intervention
Number of subjects: 92
Study 21710480 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 ml butyl‐2‐cyanoacrylate tissue glue (Glubran(®))
Number of subjects: 302
Study 21710480 — intervention group
Group type: COMPARATOR
Intervention: Absorbable polyglycolic acid 3/0 sutures (Dexon(®))
Number of subjects: 302
Study 19628107 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-divided supplementation regimen (TDR)
Number of subjects: 13
Study 19628107 — intervention group
Group type: COMPARATOR
Intervention: Time-focused supplementation regimen (TFR)
Number of subjects: 13
Study 16431305 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg once daily
Number of subjects: 282
Study 16431305 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole 30 mg twice daily
Number of subjects: 282
Study 15587751 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol (0.5 microg/day) and calcium (1000 mg/day)
Number of subjects: 70
Study 15587751 — intervention group
Group type: COMPARATOR
Intervention: Calcium (1000 mg/day) alone
Number of subjects: 70
Study 15587751 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group (30 healthy women)
Number of subjects: 70
Study 11502785 — intervention group
Group type: EXPERIMENTAL
Intervention: GH administration (20 microg/kg BW)
Number of subjects: 110
Study 11502785 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex hormone administration (hormone replacement therapy in women, testosterone enanthate in men)
Number of subjects: 110
Study 11502785 — intervention group
Group type: COMPARATOR
Intervention: GH administration
Number of subjects: 110
Study 11502785 — intervention group
Group type: COMPARATOR
Intervention: GH + testosterone enanthate
Number of subjects: 110
Study 11502785 — intervention group
Group type: COMPARATOR
Intervention: Testosterone enanthate
Number of subjects: 110
Study 11502785 — intervention group
Group type: COMPARATOR
Intervention: GH administration, testosterone enanthate, GH + testosterone enanthate
Number of subjects: 110
Study 9426995 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 1 g (CIP1)
Number of subjects: 74
Study 9426995 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg b.i.d. for 1 day (CIP2)
Number of subjects: 74
Study 9426995 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline 100 mg b.i.d. for 3 days (D)
Number of subjects: 74
Study 9426995 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antibiotics)
Number of subjects: 74
Study 8296092 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD 103-HgR vaccine (5 x 10^9 FU)
Number of subjects: 81
Study 8296092 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5 x 10^9 heat-killed E. Coli K12)
Number of subjects: 81
Study 8296092 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD 103-HgR vaccine
Number of subjects: 81
Study 8296092 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 6342841 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol, 160 mg/day
Number of subjects: 560
Study 6342841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 560
Study 6342841 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 560
Study 30958567 — intervention group
Group type: EXPERIMENTAL
Intervention: Open flap debridement (OFD) and citric acid decontamination (CAD)
Number of subjects: 23
Study 30958567 — intervention group
Group type: EXPERIMENTAL
Intervention: Open flap debridement (OFD), citric acid decontamination (CAD) and subepithelial connective tissue graft (SCTG)
Number of subjects: 23
Study 30958567 — intervention group
Group type: EXPERIMENTAL
Intervention: Open flap debridement (OFD), citric acid decontamination (CAD) and implantoplasty
Number of subjects: 23
Study 30150192 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic powder (GP) at a dose rate of 2 g/day
Number of subjects: 80
Study 30150192 — intervention group
Group type: EXPERIMENTAL
Intervention: Coriander seed powder (CSP) at a dose rate of 2 g/day
Number of subjects: 80
Study 30150192 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixture of garlic powder and coriander seed powder (1:1 dry weight basis) at a dose rate of 2 g/day
Number of subjects: 80
Study 30150192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 26219667 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV)
Number of subjects: 27
Study 26219667 — intervention group
Group type: COMPARATOR
Intervention: Standard exercise (EXE)
Number of subjects: 27
Study 25390871 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrylic resin-based resilient liner (ARL)
Number of subjects: 74
Study 25390871 — intervention group
Group type: COMPARATOR
Intervention: Conventional acrylic resin denture (CARD)
Number of subjects: 74
Study 22161771 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR-TKI (Gefitinib or Erlotinib)
Number of subjects: 1021
Study 22161771 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (platinum-based doublet)
Number of subjects: 1021
Study 19351383 — intervention group
Group type: EXPERIMENTAL
Intervention: escitalopram
Number of subjects: 240
Study 19351383 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 240
Study 17725303 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil (10 mg to 20 mg for 2 months)
Number of subjects: 60
Study 17725303 — intervention group
Group type: COMPARATOR
Intervention: Sertraline (50 mg daily for 2 months)
Number of subjects: 60
Study 17021414 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-line Cobb method for measuring lumbar lordosis
Number of subjects: 109
Study 15470715 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential irinotecan plus bolus 5‐FU/LV (Arm B)
Number of subjects: 108
Study 15470715 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin plus bolus 5‐FU/LV (Arm E)
Number of subjects: 108
Study 10579705 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 8914949 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-rich fish oil capsules containing 1.5-1.8 g of DHA
Number of subjects: 24
Study 8914949 — intervention group
Group type: COMPARATOR
Intervention: Control oil capsules containing 97% soybean oil and 3% fish oil
Number of subjects: 24
Study 1830565 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorprothixene
Number of subjects: 0
Study 1830565 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 0
Study 6336865 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin + Tobramycin (C + T)
Number of subjects: 102
Study 6336865 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole + Tobramycin (M + T)
Number of subjects: 102
Study 6336865 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole + Tobramycin (M + T) in second phase
Number of subjects: 102
Study 30773058 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention of ≥150 min of moderate-intensity activity per week
Number of subjects: 41
Study 30773058 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 41